<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombolysis with tissue plasminogen activator (tPA) is the only pharmacotherapy available for <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the use of tPA can increase the risk of <z:mp ids='MP_0001914'>hemorrhage</z:mp> due to blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) breakdown </plain></SENT>
<SENT sid="2" pm="."><plain>Recent evidence suggests that increased activation of matrix metalloproteinases (MMPs) may be involved in this breakdown </plain></SENT>
<SENT sid="3" pm="."><plain>This study examines the temporal profile of MMP-2 and -9 following tPA administration to ischemic rats </plain></SENT>
<SENT sid="4" pm="."><plain>Male Sprague-Dawley rats were randomly assigned to one of four groups (Sham-tPA; Sham-Saline; <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-tPA; <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-Saline; group n = 6, total N = 120) </plain></SENT>
<SENT sid="5" pm="."><plain>Focal embolic <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> through injection of an autologous clot </plain></SENT>
<SENT sid="6" pm="."><plain>One hour post-surgery, tPA (10 mg/kg) or saline was delivered intravenously and animals were euthanized at 3, 6, 12, or 24 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was measured by TTC staining; <z:chebi fb="2" ids="33602">BBB</z:chebi> components examined immunohistochemically; and MMP activation measured by gelatin zymography </plain></SENT>
<SENT sid="8" pm="."><plain>Our results show that tPA significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes (overall <z:mpath ids='MPATH_124'>infarct</z:mpath> volume-Sham-tPA: 5.80 +/- 4.55 [mean +/- SE]; Sham-Saline: 5.00 +/- 4.23; <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-tPA: 186.1 +/- 73.45; <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-Saline: 284.8 +/- 88.74; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with tPA was also associated with the activation of MMP-9 at 6, 12, and 24 h following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>No temporal changes were observed in MMP-2 activation, although tPA administration increased its activity compared to saline treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Analyses of immunohistochemistry showed that destruction of components of the <z:chebi fb="2" ids="33602">BBB</z:chebi> followed MMP-9 activation </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, increased MMP-9 activation may, in part, be responsible for the increases in hemorrhagic transformation reported with use of tPA </plain></SENT>
<SENT sid="13" pm="."><plain>Our study is the first to demonstrate the temporal profile of MMP activation following thrombolysis with tPA in a model of thrombotic focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>